

## Annex

**Table1. Summary of current evidence on costs and cost effectiveness of COVID-19 oral antivirals**

Treatment	Study Country	Institution	Full Treatment / drug cost (US\$)	Total cost per patient (compared to usual care)	Trial Efficacy (Nb. Populations may not be directly comparable)	Outcome (compared to usual care)	Cost-Effectiveness
<b>Paxlovid</b> (Nirmatrelvir/r itonavir)	USA	<a href="#">Institute for Clinical and Economic Review</a>	\$529	\$806	88 percent relative risk reduction of COVID-19-related hospitalization or death	0.039 QALYs gained per person treated	\$21,000 per QALY
<b>Molnupiravir</b>	USA	<a href="#">Institute for Clinical and Economic Review</a>	\$707	\$805	30 percent relative risk reduction of COVID-19-related hospitalization or death	0.0133 QALYs gained per person treated	\$61,000 per QALY
<b>Paxlovid</b> (Nirmatrelvir/r itonavir)	Korea	<a href="#">Boston Medical Center</a>	\$700	\$681	88 percent relative risk reduction of COVID-19-related hospitalization or death	0.077 severe cases averted per person treated	\$8,878 per prevented severe case averted
<b>Molnupiravir</b>	Korea	<a href="#">Boston Medical Center</a>	\$700	\$696	30 percent efficacy for reducing admission	0.024 severe cases averted per person treated	\$28,492 per prevented severe case averted
<b>Molnupiravir</b>	USA	<a href="#">Merck &amp; Co</a>	\$707	-\$895*	30 percent relative risk reduction of COVID-19-related hospitalization or death	0.210 QALYs gained per person treated	Cost Saving

\*A negative value means the oral antiviral treatment is cost saving when compared to usual care for COVID-19